oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 31 )

2018 ( 44 )

2017 ( 42 )

2016 ( 47 )

Custom range...

Search Results: 1 - 10 of 14786 matches for " Christian Marth "
All listed articles are free for downloading (OA Articles)
Page 1 /14786
Display every page Item
Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening
Willi Oberaigner, Wolfgang Buchberger, Thomas Frede, Rudolf Knapp, Christian Marth, Uwe Siebert
BMC Public Health , 2010, DOI: 10.1186/1471-2458-10-86
Abstract: To study time trends in breast cancer incidence and mortality, we applied the age-period-cohort model by Poisson regression to the official mortality data covering more than three decades from 1970 to 2006 and to the incidence data ranging from 1988 to 2006. In addition, for incidence data we analysed data on breast cancer staging and compared these with EU guidelines.For the analysis of time trend in breast cancer mortality in age groups 40-79, an age-period-cohort model fits well and shows for years 2002-2006 a statistically significant reduction of 26% (95% CI 13%-36%) in breast cancer mortality as compared to 1992-1996.We see only slight non-significant increases in breast cancer incidence. For the past five years, incidence data show a 10% proportion of in situ cases, and of 50% for cases in stages II+.The opportunistic breast cancer screening programme in Tyrol has only in part exploited the mortality reduction known for organised screening programmes. There seems to be potential for further improvement, and we recommend that an organised screening programme and a detailed screening database be introduced to collect all information needed to analyse the quality indicators suggested by the EU guidelines.Breast cancer (BC) is the leading cause of female cancer death in all industrialised countries (and also worldwide) and the breast is also the leading incident cancer site for females [1]. Therefore, screening methods for BC are of greatest public health importance. Efficiency and efficacy of organised mammography screening programmes have been proven in large randomised trials conducted in Europe and North America. For several years already, organised mammography screening programmes have been recommended in the EU[2]. Austria is one of the European countries where up to 2006 no organised programmes were implemented, but where coverage in spontaneous mammography screening could have been rather high. In a micro-census conducted in Austria in 2006-2007, more tha
Introduction of organised mammography screening in tyrol: results of a one-year pilot phase
Willi Oberaigner, Wolfgang Buchberger, Thomas Frede, Martin Daniaux, Rudolf Knapp, Christian Marth, Uwe Siebert
BMC Public Health , 2011, DOI: 10.1186/1471-2458-11-91
Abstract: In June 2007, the system of opportunistic mammography screening in Tyrol was changed to an organised system by introducing a personal invitation system, a training program, a quality assurance program and by setting up a screening database. All procedures are noted in a written protocol. Most EU recommendations for organised mammography screening were followed, except double reading. All women living in Tyrol and covered by social insurance are now invited for a mammography, in age group 40-59 annually and in age group 60-69 biannually. Screening mammography is offered mainly by radiologists in private practice. We report on the results of the first year of piloting organised mammography screening in two counties in Tyrol.56,432 women were invited. Estimated participation rate was 34.5% at one year of follow-up (and 55.5% at the second year of follow-up); 3.4% of screened women were recalled for further assessment or intermediate screening within six months. Per 1000 mammograms nine biopsies were performed and four breast cancer cases detected (N = 68). Of invasive breast cancer cases 34.4% were ≤ 10 mm in size and 65.6% were node-negative. In total, six interval cancer cases were detected during one year of follow-up; this is 19% of the background incidence rate.In the Tyrolean breast cancer screening program, a smooth transition from a spontaneous to an organised mammography screening system was achieved in a short time and with minimal additional resources. One year after introduction of the screening program, most of the quality indicators recommended by the European guidelines had been reached.However, it will be necessary to introduce double reading, to change the rule for BI-RADS 3, and to concentrate on actions toward improving the participation rate.Breast cancer is the leading cause of female cancer death in all industrialised countries (and also worldwide), and the breast is also the leading incident cancer site for females [1]. Therefore, screening metho
Frauenheilkunde 2023
Marth C
Speculum - Zeitschrift für Gyn?kologie und Geburtshilfe , 2003,
Abstract:
Margination of white blood cells - a computational approach by a hydrodynamic phase field model
Wieland Marth,Axel Voigt
Physics , 2015,
Abstract: We numerically investigate margination of white blood cells and demonstrate the dependency on a number of conditions including hematocrit, the deformability of the cells and the Reynolds number. A detailed mesoscopic hydrodynamic Helfrich-type model is derived, validated and used for the simulations to provides a quantitative description of the margination of white blood cells. Previous simulation results, obtained with less detailed models, could be confirmed, e.g. the largest probability of margination of white blood cells at an intermediate range of hematocrit values and a decreasing tendency with increasing deformability. The consideration of inertia effects, which become of relevance in small vessels, also shows a dependency and leads to less pronounced margination of white blood cells with increasing Reynolds number.
Haplotype-based variant detection from short-read sequencing
Erik Garrison,Gabor Marth
Quantitative Biology , 2012,
Abstract: The direct detection of haplotypes from short-read DNA sequencing data requires changes to existing small-variant detection methods. Here, we develop a Bayesian statistical framework which is capable of modeling multiallelic loci in sets of individuals with non-uniform copy number. We then describe our implementation of this framework in a haplotype-based variant detector, FreeBayes.
Favorable prognostic value of SOCS2 and IGF-I in breast cancer
Michael C Haffner, Barbara Petridou, Jean Peyrat, Fran?oise Révillion, Elisabeth Müller-Holzner, Günter Daxenbichler, Christian Marth, Wolfgang Doppler
BMC Cancer , 2007, DOI: 10.1186/1471-2407-7-136
Abstract: We determined the mRNA expression levels of SOCS1, SOCS2, SOCS3, CIS and IGF-I in 89 primary breast cancers by reverse transcriptase PCR. SOCS2 protein expression was further evaluated by immuno-blot and immunohistochemistry.SOCS2 expression inversely correlated with histopathological grade and ER positive tumors exhibited higher SOCS2 levels. Patients with high SOCS2 expression lived significantly longer (108.7 vs. 77.7 months; P = 0.015) and high SOCS2 expression proved to be an independent predictor for good prognosis (HR = 0.45, 95% CI 0.23 – 0.91, P = 0.026). In analogy to SOCS2, high IGF-I expression was an independent predictor for good prognosis in the entire patient cohort. In the subgroup of patients with lymph-node negative disease, high IGF-I was a strong predictor for favorable outcome in terms of overall survival and relapse free survival (HR = 0.075, 95% CI 0.014 – 0.388, P = 0.002).This is the first report on the favorable prognostic value of high SOCS2 expression in primary mammary carcinomas. Furthermore a strong association of high IGF-I expression levels with good prognosis was observed especially in lymph-node negative patients. Our results suggest that high expression of the STAT5 target genes SOCS2 and IGF-I is a feature of differentiated and less malignant tumors.SOCS proteins comprise a family of eight members (SOCS1-7 and CIS), which have initially been described as STAT induced STAT inhibitors or more generally as negative regulators of cytokine signaling via the Jak/Stat pathway. Their ability to modulate signal transduction is based on two functional domains, an SH2 domain, which binds to phosphorylated tyrosine residues and a SOCS box, which serves as a recruiting site for ubiquitin ligases [1]. Recent reports, showing the interaction of SOCS proteins with various other signaling molecules like p65, FAK, c-kit, IRS1/2 and vav, indicate a more general role of SOCSs proteins in the maintenance of cellular homeostasis [2-6]. Tumors often e
Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report
Stephan Braun, Daniel Reimer, Isolde Strobl, Ulrike Wieland, Petra Wiesbauer, Elisabeth Müller-Holzner, Siegfried Fessler, Arthur Scherer, Christian Marth, Alain G Zeimet
Journal of Medical Case Reports , 2011, DOI: 10.1186/1752-1947-5-316
Abstract: We present a well-documented case of a 29-year-old Caucasian woman who was found, through routine conventional cervical cytology screening, to have pathologic Papanicolaou (Pap) grade III D lesions (squamous cell abnormalities). She subsequently died as a result of human papillomavirus type 18-associated cervical cancer after she refused all recommended curative therapeutic procedures over a period of 13 years.This case clearly demonstrates a caveat against the promotion and use of complementary alternative medicine as pseudo-immunologic approaches outside evidence-based medicine paths. It also demonstrates the impact of the individualized demands in diagnosis, treatment and palliative care of patients with advanced cancer express their will to refuse evidence-based treatment recommendations.Cases of intra-epithelial disease of the cervix are almost entirely attributable to human papillomavirus (HPV) infection. A minority of women exposed to HPV develop a persistent infection that affects the squamocolumnar junction where the ectocervix and endocervix meet. Within that junction, dynamic changes of the epithelium occur due to puberty, pregnancy, menopause and hormonal stimulation. The epithelium is vulnerable to noxae associated with smoking, contraceptive use and infection with other sexually transmitted diseases. Alterations of the epithelium are assessed by conventional cervical cytology screening and are scored according to either the Bethesda or the Papanicolaou system. The occurrence of reactive changes and/or cell abnormalities triggers either repetitions of the cytology screening to exclude temporary alterations or a cervical biopsy for histological diagnosis of cervical intra-epithelial neoplasia and cervical cancer. With the advent of HPV vaccination [1] and HPV screening [2] to identify women at risk of lesions with atypical or malignant cells prior to clinical manifestation, in current clinical practice a patient's HPV status should play a central role in
Role of pertuzumab in the treatment of HER2-positive breast cancer
Hubalek M, Brantner C, Marth C
Breast Cancer: Targets and Therapy , 2012, DOI: http://dx.doi.org/10.2147/BCTT.S23560
Abstract: le of pertuzumab in the treatment of HER2-positive breast cancer Review (2654) Total Article Views Authors: Hubalek M, Brantner C, Marth C Published Date May 2012 Volume 2012:4 Pages 65 - 73 DOI: http://dx.doi.org/10.2147/BCTT.S23560 Received: 01 March 2012 Accepted: 13 March 2012 Published: 28 May 2012 Michael Hubalek, Christine Brantner, Christian Marth Brustgesundheitzentrum Tirol, Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria Abstract: Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising new anti-HER2 agent with a novel mechanism of action targeting the inhibition of HER2 dimerization. Nonclinical and clinical data to date indicate that pertuzumab provides a broader HER2 blockade through the inhibition of HER2 heterodimerization. In preclinical experiments, pertuzumab has demonstrated superior antitumor effects when combined with other anti-HER2 treatments such as trastuzumab, compared to when used as monotherapy. Trastuzumab and pertuzumab monoclonal antibodies bind to distinct epitopes on the HER2 receptor without competing with each other, resulting in distinctive mechanisms for disrupting HER2 signaling. These mechanisms are complementary and result in augmented therapeutic efficacy when pertuzumab and trastuzumab are given in combination. Clinically, pertuzumab may have optimal therapeutic effects when given to patients with HER2-positive cancers, in combination with trastuzumab. This observation is supported by recent clinical trials in the metastatic as well as neoadjuvant setting. Intravenous pertuzumab had an acceptable tolerability profile when added to trastuzumab and chemotherapy. This overview will review recent advances in the clinical development of this HER2-targeted therapy.
Role of pertuzumab in the treatment of HER2-positive breast cancer
Hubalek M,Brantner C,Marth C
Breast Cancer: Targets and Therapy , 2012,
Abstract: Michael Hubalek, Christine Brantner, Christian MarthBrustgesundheitzentrum Tirol, Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, AustriaAbstract: Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising new anti-HER2 agent with a novel mechanism of action targeting the inhibition of HER2 dimerization. Nonclinical and clinical data to date indicate that pertuzumab provides a broader HER2 blockade through the inhibition of HER2 heterodimerization. In preclinical experiments, pertuzumab has demonstrated superior antitumor effects when combined with other anti-HER2 treatments such as trastuzumab, compared to when used as monotherapy. Trastuzumab and pertuzumab monoclonal antibodies bind to distinct epitopes on the HER2 receptor without competing with each other, resulting in distinctive mechanisms for disrupting HER2 signaling. These mechanisms are complementary and result in augmented therapeutic efficacy when pertuzumab and trastuzumab are given in combination. Clinically, pertuzumab may have optimal therapeutic effects when given to patients with HER2-positive cancers, in combination with trastuzumab. This observation is supported by recent clinical trials in the metastatic as well as neoadjuvant setting. Intravenous pertuzumab had an acceptable tolerability profile when added to trastuzumab and chemotherapy. This overview will review recent advances in the clinical development of this HER2-targeted therapy.Keywords: HER2, breast cancer, pertuzumab, trastuzumab
A mechanism for cell motility by active polar gels
Wieland Marth,Simon Praetorius,Axel Voigt
Quantitative Biology , 2014, DOI: 10.1098/rsif.2015.0161
Abstract: We analyse a generic motility model, with the motility mechanism arising by contractile stress due to the interaction of myosin and actin. A hydrodynamic active polar gel theory is used to model the cytoplasm of a cell and is combined with a Helfrich-type model to account for membrane properties. The overall model allows to consider motility without the necessity for local adhesion. Besides a detailed numerical approach together with convergence studies for the highly nonlinear free boundary problem, we also compare the induced flow field of the motile cell with that of classical squirmer models and identify the motile cell as a puller or pusher, depending on the strength of the myosin-actin interactions.
Page 1 /14786
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.